Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
BMC Pediatrics|January 30, 2022
Feasibility and potential efficacy of a guided internet- and mobile-based CBT for adolescents and young adults with chronic medical conditions and comorbid depression or anxiety symptoms (youthCOACHCD): a randomized controlled pilot trialA Geirhos, M Domhardt, F Lunkenheimer, et al.
ACS Central Science|March 2, 2022
NP Analyst: An Open Online Platform for Compound Activity MappingSanghoon Lee, Jeffrey A van Santen, Nima Farzaneh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 17, 2016
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated MiceMarie-Louise Sentman, Joana M Murad, W James Cook, et al.
European Radiology|June 9, 2009
MR-lymphangiography at 3.0 T--a feasibility studyMike Notohamiprodjo, Ruediger G H Baumeister, Tobias F Jakobs, et al.
Journal of Natural Products|April 13, 2023
Interaction Metabolomics to Discover Synergists in Natural Product MixturesWarren S Vidar, Tim U H Baumeister, Lindsay K Caesar, et al.
Der Nervenarzt|February 7, 2018
[Psychotherapy of depressive disorders: Evidence in chronic depression and comorbidities]M Härter, A Jansen, M Berger, et al.
Der Nervenarzt|February 1, 2018
[Psychotherapy of depressive disorders : Procedures, evidence and perspectives]R Meister, A Jansen, M Berger, et al.
ESMO Open|September 5, 2021
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX studyK Klinghammer, J Fayette, A Kawecki, et al.
Zeitschrift Fur Arztliche Fortbildung Und Qualitatssicherung|October 19, 2004
[The German Guideline Clearinghouse on Breast Cancer: the need for frequent updating of breast cancer guidelines requires effective guideline updating procedures]Olaf Weingart, Dietrich Sonntag, Henrike Trapp, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
Pageof 10